

Correction

# Correction: Srinivasan Rajsri et al. Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection. *Cancers* 2023, 15, 2866

Kritika Srinivasan Rajsri <sup>1,2</sup> , Nainita Roy <sup>1</sup> and Sohini Chakraborty <sup>1,\*</sup> 

<sup>1</sup> Department of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA; ks3144@nyu.edu (K.S.R.)  
<sup>2</sup> Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY 10010, USA  
 \* Correspondence: sohini.chakraborty@nyulangone.org

## Missing Citation

In the original publication [1], ref. [84] was not cited. The citation has now been inserted in Figure 1 caption and should read:

84. Hourigan, C.S.; Karp, J.E. Minimal residual disease in acute myeloid leukaemia. *Nat. Rev. Clin. Oncol.* **2013**, *10*, 460–471. <https://doi.org/10.1038/nrclinonc.2013.100>.

## Figure Legend

In the original publication, there was a mistake in the illustration and legend for Figure 1. The graph at the bottom of the figure was improperly labeled in the X-axis, and the figure legend was not written correctly. The correct illustration and legend appear below.




**Citation:** Srinivasan Rajsri, K.; Roy, N.; Chakraborty, S. Correction: Srinivasan Rajsri et al. Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection. *Cancers* 2023, 15, 2866. *Cancers* **2024**, *16*, 954. <https://doi.org/10.3390/cancers16050954>

Received: 21 August 2023  
 Accepted: 15 November 2023  
 Published: 27 February 2024



**Copyright:** © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).



**Figure 1.** A schematic illustration and description of the clinical MRD detection methods. Panels: 1. Morphology, 2. MFC, 3. PCR, and 4. NGS [18]. Panel 2.2 also demonstrates the LSC investigational detection methods recommended for evaluation in clinical studies [70]. Panel 5 describes the detection threshold of the various detection methods, and is inspired by [84] (Figure 1).

---

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

## Reference

1. Srinivasan Rajsri, K.; Roy, N.; Chakraborty, S. Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection. *Cancers* **2023**, *15*, 2866. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.